

Six-Year Long-Term Safety and Efficacy of Golodirsén in Patients With DMD vs Mutation-Matched External Controls

Francesco Muntoni,^{1,2} Andreea M. Seferian,³ Volker Straub,⁴ Michela Guglieri,⁴ Laurent Servais,^{5,6} Ewa Wilk-Durakiewicz,⁷ Xiao Ni,⁷ Ping Gao,⁷ Menghan Hu,⁷ Joel Iff,⁷ Lorna Hill,⁷ Ihor Sehinovych,⁷ Larry Orogun,⁷ Eugenio Mercuri^{8,9}

¹Dubowitz Neuromuscular Centre, University College London, Great Ormond Street Institute of Child Health, London, UK; ²National Institute for Health Research Great Ormond Street Hospital Biomedical Research Centre, London, UK; ³Assistance Publique Hôpitaux de Paris, Sorbonne Université, Institut de Myologie, AFM-Téléthon, Essais Cliniques I-Motion Enfants, Hôpital Armand Trousseau, Paris, France; ⁴John Walton Muscular Dystrophy Research Center, Translational and Clinical Research Institute, Newcastle University and Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK; ⁵Centre de Références des Maladies Neuromusculaires, Department of Pediatrics, University Hospital Liège & University of Liège, Liège, Belgium; ⁶MDCU Oxford Neuromuscular Centre & NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK; ⁷Sarepta Therapeutics, Inc., Cambridge, MA; ⁸Pediatric Neurology Unit, Università Cattolica del Sacro Cuore Roma, Rome, Italy; ⁹Nemo Clinical Centre, Fondazione Policlinico Universitario A Gemelli IRCCS, Rome, Italy



Please scan QR code for full study details

Objective

To describe results from Study 4053-101 (NCT02310906) and the open-label extension (OLE), Study 4045-302 (NCT03532542), evaluating the safety and efficacy of golodirsén treatment up to ~6 years in patients amenable to exon 53 skipping with progressive disease deterioration

Key Findings

This is the longest follow-up of safety and functional benefit of golodirsén in a declining Duchenne muscular dystrophy (DMD) population

BACKGROUND


- DMD is a fatal, X-linked neuromuscular disease caused by mutations in the dystrophin (DMD) gene resulting in the lack of dystrophin protein¹
- Patients with DMD aged ≤7 years treated with corticosteroids may have improved functional tests due to the effect of physiologic growth and development, whereas those aged >7 years tend to exhibit progressive deterioration and declining ambulatory function, with loss of ambulation (LOA) occurring at age ~13 years¹⁻⁴
- Mutations leading to deletions flanking exon 53 account for up to 8% of all patients with DMD⁵; natural history studies demonstrate disparate disease trajectories for patients with different mutations⁶
- Golodirsén binds to dystrophin pre-mRNA to allow skipping of exon 53, which restores the mRNA reading frame and allows for production of an internally shortened functional dystrophin protein⁷
- Study 4053-101, a first-in-human, phase 1/2, 2-part clinical trial, provided evidence for long-term safety of golodirsén and suggested functional benefit vs matched external controls (ECs) in patients with mutations amenable to exon 53 skipping who have progressive deterioration and declining ambulatory function⁸

CONCLUSIONS

- Golodirsén treatment for up to 6 years demonstrates a favorable, consistent safety profile and post hoc analyses support its long-term efficacy vs matched EC patients
 - Safety was consistent with previous clinical and real-world experience
 - Time to LOA suggests benefit in ambulation from golodirsén treatment, although the analysis is limited due to unavailability of follow-up for the matched EC patients
 - Pulmonary decline based on FVC%p function was associated with significant attenuation
- These data provide the longest follow-up to date of safety and functional outcomes of golodirsén in a declining DMD population of patients with mutations amenable to exon 53 skipping

STUDY DESIGN

- Study 4045-302 is a 3-year multicenter, OLE study evaluating the long-term safety and efficacy of golodirsén 30 mg/kg in patients with DMD amenable to skipping of exon 53
- Patients from Study 4053-101 were eligible to transfer into the 3-year OLE



Assessments

- Incidence of serious adverse events (AEs)
- Ambulatory function over 6 years by LOA
 - LOA was defined as meeting at least one of the following criteria: 1) 2 consecutive visits of either North Star Ambulatory Assessment (NSAA) walk score 0, or inability to complete 10-meter walk run (10MWR) test, or a 10MWR time >30 seconds, or 2) continuous wheelchair use or other documented information indicating age at LOA
 - This expanded definition of LOA was used because frequent NSAA administration was not available for the matched EC patients due to a sparse visit schedule or lack of NSAA assessment
- Pulmonary function by percent predicted forced vital capacity (FVC%p)

Post hoc analyses (scan QR code for full study details)

- Golodirsén-treated patients were compared with matched EC patients (for age, mutation, steroid use, ambulation at baseline) for ambulatory function or with matched EC patients (for age, mutation, steroid use, FVC%p at baseline) for pulmonary function
- Aside from ambulation status, baseline functional parameters were not available for all the mutation-matched EC patients; however, since LOA is a time-to-event milestone, it is less influenced by bias compared with intermediate functional trajectory analyses

RESULTS

Safety

- At the last assessment prior to golodirsén initiation, 25 patients were a mean (SD) age of 8.4 (2.2) years; 18/25 (72%) completed the OLE up to 338.6 weeks (6.49 years)
- Over 6 years, golodirsén was well tolerated: treatment-emergent adverse events (TEAEs) were generally mild, nonserious, and unrelated to treatment
 - Most common TEAEs were vomiting (18/25; 72%), cough (16/25; 64%), nasopharyngitis (15/25; 60%), headache (14/25; 56%), and back pain (13/25; 52%)
- No evidence of kidney toxicity and no TEAEs leading to treatment discontinuations or deaths up to 6 years
- Among 8 patients with implanted ports; no port-related infections occurred during the OLE
- TEAEs and TEAEs possibly related to treatment decreased in the OLE (4–6 years) compared with the parent study (0–3 years)

Adverse Events Overview

	Golodirsén (0–3 years) ^a (N=25)	Golodirsén (4–6 years) (N=25)	Golodirsén (0–6 years) (N=25)
Patients with ≥1 TEAE, n (%)	25 (100)	19 (76)	25 (100)
Possibly related to study drug	9 (36)	6 (24)	15 (60) ^a
Serious	4 (16)	5 (20)	8 (32) ^b
Total TEAEs by severity, n	860	408	1268
Mild	831	360	1191
Moderate	24	42	66
Severe	5	6	11

^aNo cases confirmed related to study drug. ^bOne patient had serious AEs in both the parent and the OLE study so was not counted twice in the total.

- 8/25 (32%) patients experienced 11 severe TEAEs, including fractures (n=4), LOA (n=6), and scoliosis (n=1); none were considered related to treatment
- 8/25 (32%) patients experienced 17 serious AEs, including fractures (n=4), pyrexia (n=1), and convulsion (n=1); none were considered related to treatment

Golodirsén prolonged ambulation compared with matched exon 53 skip-amenable EC patients

- Over 3 years, LOA occurred in 4/25 (16.0%) of golodirsén-treated patients compared with 12/54 (22.2%) of matched EC patients, representing a 91.1% risk reduction (hazard ratio [HR], 0.089; $P=0.022$)
 - Median time to LOA was not reached for both golodirsén-treated and matched EC patients since there were not enough events observed during the duration of follow-up for this analysis to reach 50% of patients with LOA
- Over 6 years, 15 golodirsén-treated patients experienced LOA (10.7–19.5 years old), with 7 patients still ambulant at OLE completion (12.4–20.3 years old)
- Compared with matched EC patients (n=19), golodirsén-treated patients experienced a median delay in time to LOA of ~2.4 years, suggesting a 47.4% risk reduction (HR, 0.526; $P=0.149$)
 - Due to unavailability of follow-up for matched EC patients up to 6 years, this analysis may need to be interpreted with caution

Baseline Characteristics to Show Matching Comparability


	Golodirsén (N=25)	CINRG ^a +PRO-DMD ¹⁰ (for 3-year time to LOA analysis) (N=54)	CINRG ^b (for 6-year time to LOA analysis) (N=19)
Age, years	8.8 (2.15) ^a	8.8 (2.46)	8.4 (2.14)
Race, n (%)			
White	23 (92.0)	47 (87.0)	15 (78.9)
Black		1 (1.9)	
Asian		5 (9.3)	4 (21.1)
Other	2 (8.0)	1 (1.9)	
Weight, kg	28.4 (9.01)	28.7 (12.25)	28.1 (10.03)
Height, cm	120.6 (10.38)	122.2 (12.66)	120.2 (10.06)
BMI, kg/m ²	18.9 (3.79)	18.6 (4.13)	19.0 (4.38)
Total time on treatment during study, days ^b	1162.0 (181.64)	933.8 (640.27)	1243.6 (963.03)
Corticosteroid regimen, n (%)			
Prednisone or prednisolone (daily)	10 (40.0)	12 (22.2)	6 (31.6)
Deflazacort (daily)	9 (36.0)	22 (40.7)	6 (31.6)
Prednisone/prednisolone (intermittent)	3 (12.0)	11 (20.4)	5 (26.3)
Others ^c	3 (12.0)	8 (14.8)	1 (5.3)
Unknown	0 (0.0)	1 (1.9)	1 (5.3)

Values are mean (SD) unless otherwise stated. ^aBaseline age at the time of golodirsén initiation. ^bTreatment refers to SOC (steroid) for EC patients and to total time on golodirsén during the study for the golodirsén-treated patients. ^cOthers: deflazacort (2 days/week; intermittent; weekends only; other dosing); methylprednisolone (continuous). BMI=body mass index; CINRG=Cooperative International Neuromuscular Research Group; EC=external control; LOA=loss of ambulation; SOC=standard of care.


Golodirsén treatment attenuated pulmonary decline compared with mutation-matched EC patients

- Golodirsén-treated patients (≥10 years) experienced a statistically significant and clinically meaningful attenuation in annual FVC%p decline compared with matched EC patients (2.9% vs 6.6%, respectively; $P<0.01$) (see poster P149 for full details of pulmonary analysis)

At 3 years, there was a 91.1% risk reduction (HR, 0.089; $P=0.022$) in time to LOA with golodirsén



- At 6 years, there was ~2.4-year delay in time to LOA with golodirsén ($P=0.149$), representing a 47.4% risk reduction
- Median time to LOA for golodirsén-treated vs matched EC patients: 1968 days (~5.4 years) vs 1092 days (~3 years)



CINRG=Cooperative International Neuromuscular Research Group; EC=external control; HR=hazard ratio; LOA=loss of ambulation.

REFERENCES

- Birnkrant DJ, et al. *Lancet Neurol*. 2018;17:251-67.
- McDonald CM, et al. *Muscle Nerve*. 2010;42:966-74.
- Mazzone E, et al. *Neurology*. 2011;77:250-6.
- Mazzone ES, et al. *PLoS One*. 2013;8:e52512.
- Aartsma-Rus A, et al. *Hum Mutat*. 2009;30:293-9.
- Brogna C, et al. *PLoS One*. 2019;14:e0218683.
- Frank DE, et al. *Neurology*. 2020;94(21):e2270-e2282.
- Servais L, et al. *Nucleic Acid Ther*. 2022;32(1):29-39.
- ClinicalTrials.gov. NCT00468832. <https://clinicaltrials.gov/ct2/show/NCT00468832> [Accessed August 31, 2023].
- ClinicalTrials.gov. NCT01753804. <https://clinicaltrials.gov/ct2/show/NCT01753804> [Accessed August 31, 2023].

ACKNOWLEDGMENTS & DISCLOSURES

The authors and Sarepta Therapeutics, Inc., thank the patients and their families. Study 3045-302 (NCT02500381) was funded by Sarepta Therapeutics, Inc. Editorial support was provided by Paraskevi Briassoulis, PhD, of Eloquent Scientific Solutions and was funded by Sarepta Therapeutics, Inc. Disclosures: FM: Received consultant fees and speaker honoraria from Sarepta Therapeutics, Inc. AMS, MG, LS: Received speaker honoraria and research collaboration from Sarepta Therapeutics, Inc. VS: Participated in advisory boards, received speaker honoraria, and has a research collaboration with Sarepta Therapeutics, Inc. EWD, XN, PG, MH, JJ, LH, IS, LO: Employees of Sarepta Therapeutics, Inc. and may own stock/options in the company. EM: Received consultant fees from Sarepta Therapeutics, Inc.



METHODS DETAILS

Study population (Study 4053-101 and Study 4045-302)

- Boys aged 6–15 years diagnosed with genotype-confirmed DMD amenable to exon 53 skipping
- Received stable dose of oral corticosteroids for ≥ 24 weeks prior to week 1
- Mean 6-minute walk test distance of ≥ 250 meters at both screening and baseline
- NSAA total score >17 and/or rise time <7 seconds (Gowers' sign)

Statistical analyses


- Adverse events were analyzed using descriptive statistics
- Ambulation data were compared post hoc with mutation-matched EC patients aged ≥ 6 years, with steroid use and able to rise at baseline, identified from CINRG-DNHS (NCT00468832)⁸ and PRO-DMD-01 (NCT01753804)⁹
- Pulmonary data were compared post hoc with mutation-matched EC patients aged ≥ 10 years, with at least 1 FVC%p assessment at age 10–12 years followed by at least 1 additional valid FVC%p assessment, identified from CINRG-DNHS (NCT00468832),⁹ PRO-DMD-01 (NCT01753804),¹⁰ or Study 301 (NCT02255552)¹¹
- The impact of golodirsen treatment on FVC%p compared with mutation-matched EC was evaluated using mixed models with repeated measures framework (response variable: FVC%p; fixed effects: treatment group, age at visit, and treatment group by age interaction; random effect: patient)



RESULTS (cont'd)

Patient disposition

- 18/25 (72%) completed the OLE up to 6.49 years




*Reasons for withdrawal were unrelated to treatment. OLE=open-label extension.

Baseline Characteristics of Golodirsen-Treated Patients (Study 4053-101)

Baseline Characteristic ^a	Golodirsen-Treated Patients (n=25)
Age, years	8.4 (2.2; range, 6–13)
Height, cm	120.5 (10.1)
Weight, kg	28.4 (9.0)
BMI, kg/m ²	19.1 (3.7)
Mutation, n (%)	
45–52	8 (32.0)
48–52	5 (20.0)
49–52	5 (20.0)
50–52	4 (16.0)
52	3 (12.0)
NSAA	23.6 (5.0; range, 13–33)
6MWT distance, m	405.8 (55.1; range, 290–512)
Time to rise from floor, s	5.9 (3.5; range, 2.3–18.6)
FVC%p	92.7 (24.0; range, 16.4–137.8)
Time since DMD diagnosis, mo	55.8 (24.8; range, 16.1–122.9)
Duration of corticosteroid use, mo	35.3 (24.4; range, 8.9–97.7)
Frequency of corticosteroid administration, n (%)	
Continuous	19 (76.0)
Intermittent	6 (24.0)
Corticosteroid type, n (%)	
Deflazacort	12 (48.0)
Prednisone	13 (52.0)

Data are mean (SD) unless otherwise stated. ^aFor golodirsen-treated patients, baseline was defined as the last assessment prior to golodirsen initiation. 6MWT=6-minute walk test; BMI=body mass index; DMD=Duchenne muscular dystrophy; FVC%p=percent predicted forced vital capacity; NSAA=North Star Ambulatory Assessment.

LOA Analysis Population Selection Flowchart



CINRG=Cooperative International Neuromuscular Research Group; EC=external control.